The studies by Khaled et al. (2016), Yamashita et al. (2016) demonstrated a higher incidence of acute GVHD in the CYP3A5*1 expresser group when compared to the CYP3A5*3 non-expresser group. The gene discussed is CYP3A5; the disease is acute graft versus host disease.